Saratov JOURNAL of Medical and Scientific Research

Natriuretic peptides and Galectin-3 in senile heart failure patients with preserved ejection fraction.

Year: 2015, volume 11 Issue: №1 Pages: 041-046
Heading: Gerontology and geriatrics Article type: Original article
Authors: Malinova L.I., Podbolotov R.A., Povarova T.V., Pletneva G.F.
Organization: Saratov State Medical University, Saratov Road Clinical Hospital, Regional Hospital for War Veterans, Saratov

Purpose: to characterize biomarker panel in senile patients with heart failure with preserved ejection fraction (HF-pEF). Material and Methods. 356 senile patients with chronic heart failure with preserved ejection fraction (HFpEF) were examined to form the study sample of 48 male patients without atrium fibrillation, anemia, diabetes mellitus, onco-pathology and missing clinical data. NT-proBNP, galectin-3 (gal-3) and proANT assay was performed by commercially available ELISA kits. Results. In patients without left ventricular (LV) regional wall motion abnormalities (RWMA). gal-3 (2,13 (0,98; 3,50) vs 5.16 (4,34;9.63) ng/mL, p = 0.011) and NT-proBNP (5,59 (1,00; 10.13) vs 32,04 (15,40; 46,18) fmol/mL, p=0,006) levels were significantly lower than in patients with LV RWMA. Contrarily proANP level was lower in patients with LV RWMA (3,24 (2,47; 3,75) vs 1,38 (0,83; 2,29) nmol/mL, p=0.071). proANP was the only biomarker to increase significantly in long livers (7,30 (4,52; 7,63) vs 2,68 (1,88; 3,32) nmol/mL, p=0.006). NT-proBNP positively correlated with glucose level and negatively with hsCRP (R=0,52, p=0,007). Conclusion. Biomarker panel in senile heart failure patients with preserved ejection fraction has characterized: increase in NT-proBNP and galectin-3 is associated with more severe clinical course and presence of regional wall motion abnormalities in senile patients.

1. Mareev VYu, Ageev FT, Arutyunov GP, et al. National HFA, RCS and RSMST guidelines for the diagnosis and treatment of chronic heart failure. Heart failure Journal 2013; 14: 379-472
2. Yancy CW, Jessup М, Bozkurt В, et al. 2013ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation / American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013; 62: e147-239
3. McMurray JJ.AdamopoulosS, Anker SD, etal. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2012; 14: 803-69
4. Lam CS, Donal E, Kraigher-Krainer E, Vasan RS. Epidemiology and clinical course of heart failure with preserved ejection fraction. Eur J Heart Fail 2011; 13: 18-28
5. Nagueh SF, Bierig SM, Budoff MJ, et al. American Society of Echocardiography clinical recommendations for multimodality cardiovascular imaging of patients with hypertrophic cardiomyop-athy: Endorsed by the American Society of Nuclear Cardiology Society for Cardiovascular Magnetic Resonance, and Society of Cardiovascular Computed Tomography. J Am Soc Echocardiogr 2011;24:473-98
6. McMurray JJ, O'Connor С Lessons from the TOPCAT trial. N Engl J Med 2014; 370: 1453-4. 7. Bursi F, Weston SA, Redfield MM, et al. Systolic and dia-stolic heart failure in the community. JAMA 2006; 296: 2209-16
8. Lee DS, Gona P, Vasan RS, et al. Relation of disease pathogenesis and risk factors to heart failure with preserved or reduced ejection fraction: insights from the framingham heart study of the national heart, lung, and blood institute. Circulation 2009; 119:3070-7
9. Strait JB, Lakatta EG. Aging-associated cardiovascular changes and their relationship to heart failure. Heart Fail Clin 2012; 8: 143-64
10. Lakatta EG. Cardiovascular aging in health. Clin Geri-atr Med 2000; 16:419-44
11. Malinova LI, Silina TS, Shuvalov SS, Denisova TP Chronic heart failure and obesity in senile patinets: diagnostic difi-culties. Clin gerontol2011; 17: 26-30
12. Zile MR, Gottdiener JS, Hetzel SJ, et al. Prevalence and significance of alterations in cardiac structure and function in patients with heart failure and a preserved ejection fraction. Circulation 2011; 124: 2491 -501
13. Pellicori P, Cleland JG. Heart failure with preserved ejection fraction. Clin Med 2014; 14 Suppl 6: s22-8
14. Penicka M, Bartunek J, Trakalova H, et al. Heart failure with preserved ejection fraction in outpatients with unexplained dyspnea: a pressure-volume loop analysis. J Am Coll Cardiol 2010; 55: 1701-10
15. Cleland JG, Taylor J, Freemantle N, Goode KM, Rigby AS, Tendera M. Relationship between plasma concentrations of N-terminal pro brain natriuretic peptide and the characteristics and outcome of patients with a clinical diagnosis of diastolic heart failure: a report from the PEP-CHF study. Eur J Heart Fail 2012; 14:487-94
16. Pellicori P, Kallvikbacka-Bennett A, Khaleva O, et al. Global longitudinal strain in patients with suspected heart failure and a normal ejection fraction: does it improve diagnosis and risk stratification? Int J Cardiovasc Imaging 2014; 30: 69-79
17. Troughton RW, Frampton CM, Nicholls MG. Biomark-er-guided treatment of heart failure: still waiting for a definitive answer. J Am Coll Cardiol 2010; 56: 2101-4
18. Felker GM, Ahmad T, Anstrom KJ, et al. Rationale and design of the GUIDE-IT study: Guiding Evidence Based Therapy Using Biomarker Intensified Treatment in Heart Failure. JACC Heart failure 2014; 2: 457-65
19. Cleland JG, Pellicori P. Defining diastolic heart failure and identifying effective therapies. JAMA 2013; 309: 825-6
20. Cappellin E, Gatti R, Spinella P, et al. Plasma atrial natriuretic peptide (ANP) fragments proANP (1-30) and proANP (31-67) measurements in chronic heart failure: a useful index for heart transplantation? Clin Chim Acta 2001; 310: 49-52
21. Ton VK, Mukherjee M, Judge DP. Transthyretin cardiac amyloidosis: pathogenesis, treatments, and emerging role in heart failure with preserved ejection fraction. Clinical Medicine Insights Cardiology 2014; 8: 39-44
22. Gorevic PD, Prelli FC, Wright J, Pras M, Frangi-one B. Systemic senile amyloidosis. Identification of a new preal-bumin (transthyretin) variant in cardiac tissue: immunologic and biochemical similarity to one form of familial amyloidotic polyneu-ropathy. J Clin Invest 1989; 83: 836-43
23. Heinisch BB, Vila G, Resl M, et al. B-type natriuretic peptide (BNP) affects the initial response to intravenous glucose: a randomised placebo-controlled cross-over study in healthy men. Diabetologia 2012; 55: 1400-5
24. Wei P, Wang HB, Fu Q, Bai J, Zhu Q. Levels of BNP and stress blood glucose in acute coronary syndrome patients and their relationships with the severity of coronary artery lesion. Cell biochemistry and biophysics 2014; 68: 535-9.

2015_01_041-046.pdf939.62 KB

No votes yet